Compare Dow Inc (DOW) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Viatris Inc — how do they compare? Dow Inc trades at $30.65 (market cap $22.58B), while Viatris Inc trades at $16.25 (market cap $18.69B). The key difference: Dow Inc is the larger of the two by market cap, and Dow Inc pays the higher dividend (4.48%). Which is the better fit depends on your goals.
| DOW | VTRS | |
|---|---|---|
Market Cap | $22.58B | $18.69B |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $17.86 |
52-Week Low | $20.65 | $9.49 |
Enterprise Value | $38.27B | $30.80B |
Dividend Yield | 4.48% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $30.58, up 4.23% today, with a neutral technical signal and bullish moving averages. Recent earnings have consistently beaten estimates, but the company reported a net loss of -$2.62B in 2025, with declining revenue and negative profit margins. Cash flow from operations improved in 2025 to $1.03B, though debt levels have risen. The stock is trading below the analyst consensus price target of $35.11, with a mixed analyst rating of 33% buy, 53% hold, and 14% sell.
The outlook is cautious; while earnings beats and a dividend payment provide some support, persistent net losses, revenue declines, and rising debt pose significant risks. Investors should weigh the potential for operational turnaround against fundamental weaknesses and macroeconomic pressures on the chemicals sector.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
